Equities research analysts predict that Steris PLC (NYSE:STE) will post earnings per share of $1.11 for the current quarter, Zacks reports. Three analysts have provided estimates for Steris’ earnings, with estimates ranging from $1.11 to $1.12. Steris reported earnings per share of $1.00 in the same quarter last year, which suggests a positive year over year growth rate of 11%. The business is scheduled to announce its next quarterly earnings results on Wednesday, August 14th.
According to Zacks, analysts expect that Steris will report full year earnings of $5.37 per share for the current fiscal year, with EPS estimates ranging from $5.35 to $5.40. For the next year, analysts anticipate that the firm will report earnings of $5.93 per share, with EPS estimates ranging from $5.90 to $5.99. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that cover Steris.
Steris (NYSE:STE) last announced its quarterly earnings results on Monday, May 13th. The medical equipment provider reported $1.53 EPS for the quarter, beating the Zacks’ consensus estimate of $1.44 by $0.09. Steris had a net margin of 10.93% and a return on equity of 13.34%. The business had revenue of $768.00 million for the quarter, compared to analyst estimates of $738.87 million. During the same quarter in the prior year, the business earned $1.24 EPS. Steris’s quarterly revenue was up 7.3% on a year-over-year basis.
In other news, CEO Walter M. Rosebrough, Jr. sold 50,000 shares of the stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $125.00, for a total transaction of $6,250,000.00. Following the completion of the sale, the chief executive officer now directly owns 98,895 shares in the company, valued at $12,361,875. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Walter M. Rosebrough, Jr. sold 119,000 shares of the firm’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $132.56, for a total transaction of $15,774,640.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 259,785 shares of company stock worth $34,402,980. Company insiders own 2.36% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. Pinebridge Investments L.P. bought a new stake in shares of Steris in the 1st quarter worth approximately $50,000. Rockefeller Capital Management L.P. purchased a new stake in shares of Steris in the 1st quarter worth about $54,000. Advisory Services Network LLC grew its position in shares of Steris by 26.0% in the 4th quarter. Advisory Services Network LLC now owns 427 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 88 shares during the period. Executive Wealth Management LLC purchased a new stake in Steris during the 4th quarter valued at about $47,000. Finally, Enlightenment Research LLC purchased a new stake in shares of Steris during the 4th quarter valued at about $53,000. 83.37% of the stock is owned by institutional investors.
STE traded down $1.22 on Friday, reaching $140.61. The company had a trading volume of 52,766 shares, compared to its average volume of 683,281. Steris has a fifty-two week low of $99.14 and a fifty-two week high of $142.98. The firm has a market cap of $12.05 billion, a P/E ratio of 28.75 and a beta of 0.96. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.82 and a current ratio of 2.27.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Wednesday, June 12th will be given a dividend of $0.34 per share. The ex-dividend date of this dividend is Tuesday, June 11th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.97%. Steris’s payout ratio is presently 27.81%.
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
Featured Story: How are the companies in the S&P 500 selected?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.